A single dose, randomised, 2-period, 2-sequence, crossover, comparative bioavailability study between R107 tablet and 60 mg ketamine IV solution administered orally in healthy male and female participants under fasting conditions.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2018
At a glance
- Drugs R 107 Radikal Therapeutics (Primary) ; Ketamine
- Indications Major depressive disorder
- Focus Pharmacokinetics
- 11 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Jul 2018 New trial record